Recent Scientific Debate
Udskriv denne side
Recent Scientific Debate:

» EACTA Survey on Transfusion Policy in European Cardiac Surgery Institutions - DOC
This survey is endorsed by EACTA and funded by an unrestricted educational grant from Novo Nordisk A/S. The results of this survey will be presented at the next EACTA Annual Meeting in Athens, May 2009, and may be used for scientific publications in peer-reviewed journals.
» Result of MCQ - TOE pilot-examination, Bergamo - PDF
» Abstracts EACTA 2004, London - PDF
» Toe education in UK
» Current status of lung protective ventilation in ARDS
Click on "Scientific Debate Archive" on menu to the left for a complete list of contributions to the debate.



Aprotinin statement
from EACTA Directory Board
Recently, the safety of Aprotinin in cardiac surgery has been called into question. Two recent papers have drawn attention to its use in this setting.(1,2).

Both of these are observational studies. The first represents patient data from the McSPI EPI-2 database, and members may be aware that a substantial number of these patients will have been drawn from the 25 European centres participating in this study.

In response to these publications, on Feb 8th 2006 the United States Food and Drug Administration ( FDA) issued an "FDA Public Health Advisory" concerning the use of Aprotinin in cardiac surgery.

The advisory can be found in full at ; www.fda.gov/CDER/drug/advisory/aprotinin.htm.

The paragraph below is extracted from the report verbatim;

".........While FDA is continuing its evaluation, we are providing the following recommendations to healthcare providers and patients:
  • Physicians who use Trasylol should carefully monitor patients for the occurrence of toxicity, particularly to the kidneys, heart, or central nervous system and promptly report adverse event information to Bayer, the drug manufacturer, or to the FDA MedWatch program, as described at the end of this advisory.



  • Physicians should consider limiting Trasylol use to those situations where the clinical benefit of reduced blood loss is essential to medical management of the patient and outweighs the potential risks......"

We are also aware of two specialist societies that have also commented on this issue.

The Society of Cardiovascular Anaesthesiologists ( SCA) comments can be found at ; www.scahq.org/sca3/aprotinin.shtml

The Association of Cardiothoracic Anaesthetists ( ACTA) comments can be found at ; www.acta.org.uk/ACTAS4Aprotonin.asp

EACTA members may be interested to read the views of these specialist societies also.

In Europe, Trasylol is licensed on a country-by-country basis, rather than centrally through the EMEA. As a result, as many members may be aware, aprotinin is not available in some EU countries. The EMEA does have a safety role even for products licensed nationally if an issue is drawn to its attention by an appropriate authority. The EMEA may therefore make a comment in due course.

There are a number of issues involved in this controversy. These include the value of observational and phase 4 studies, as well as the primary issue of the safety of Aprotinin and the extent to which these additions to the literature shed light on the subject. EACTA will endeavour to provide a lively debate for its members on these issues in the coming months.

In the meantime, for those European anaesthesiologists who have access to Aprotinin we would endorse the FDA’s recommendations.

EACTA Directory Board.

References

1.Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation.
The risk associated with aprotinin in cardiac surgery.
N Engl J Med. 2006 Jan 26;354(4):353-65.

2. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM.
A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006 Mar;46(3):327-38.

Conflict of Interest;
Bayer Inc. has supported a number of educational initiatives and programmes for EACTA



Dear EACTA member

EACTA has decided to undertake an European Survey on Perioperative Coagulation Management in Cardiac Surgery. The results of this survey will be preliminary released at our next Annual Meeting, in Venice, within the context of a dedicated Symposium. A scientific paper will be prepared and sent to a peer-reviewd journal after the Symposium. All the contributors from the participating Institutions will be mentioned in the article, in a specific appendix. We consider the possibility to include within the Authors as much as 12 names, that will be subsequently chosen on the basis of their contribution and their will to discuss the manuscript before presentation to the chosen Journal.

We are therefore asking you to fill the attached questionnaire and to send it back, via e-mail, to my address.



Of course, we will probably receive more than one contribution from a single Institution. In this case, we will settle a "mean" report for the Institution, weighting the different questionnaires.

Please complete and send the questionnaire ASAP. It just takes a few minutes

Thank you, best regards and see you all in Venice

Marco Ranucci, MD
EACTA Vice-President
EACTA 2006 Chiarman

» Questionnaire
Latest News
ACTA Nottingham
14-15th November 2013.
» Read more

17th Conference of the Indian Association of Cardiovascular and Thoracic Anaesthesiologists
21-23 February 2014,
Mumbai, India.
» Read more

EACTA Newsletter
March 2013


» Click here

EACTA Streaming
Lectures from EACTA 2012 now available on-line
» Read more

Lecture and scientific abstracts from the 2012 Annual Meeting of EACTA in Amsterdam

Please go to:
» Applied Cardiopulmonary Pathophysiology

EACTA on Linkedin
» Click here

EACTA ICU on Facebook
» Click here

EACTA Perioperative Echocardiography DVDs now available
Buy your copy as an EACTA member for €50.
» Read more

JCVA



The Journal of Cardiothoracic and Vascular Anesthesia (JCVA) is now the official journal of the European Association of Cardiothoracic Anesthesiologists (EACTA)......
» Read more